Comparing Dezocine and Nalbuphine Combined With Sufentanil for Pain Relief and Flap Outcomes After Oral Cancer Surgery

What this Trial Is About

This research aims to compare two pain relief methods for patients undergoing oral cancer radical surgery with free flap reconstruction. The study evaluates the effects of combining sufentanil with either dezocine or nalbuphine on postoperative pain, complications, and flap survival. Both drugs are opioid agonist-antagonists, possibly offering better safety than traditional opioids like sufentanil alone. This is a prospective, randomized, double-blind, controlled clinical trial involving 60 patients aged 18 to 70 years. Participants are randomly assigned to one of two groups receiving patient-controlled intravenous analgesia PCIA after surgery. One group receives sufentanil combined with dezocine, while the other receives sufentanil combined with nalbuphine. Both combinations are diluted to 150 ml with normal saline and administered via a PCIA pump that delivers a 2.5 ml bolus with a 15-minute lockout and no basal infusion. This intervention starts at the end of surgery, with standardized general anesthesia used for all patients. Throughout the study, patients pain intensity is measured using the Visual Analogue Scale at 2, 24, and 48 hours after surgery. Researchers also monitor flap survival and sensory function daily for seven days, noting any complications like hematoma or infection. Other assessments include sedation levels, adverse events such as nausea or dizziness, length of hospital stay, and intraoperative hemodynamics. The study aims to provide insights into which analgesic combination offers better pain control with fewer side effects and improved flap outcomes.

Effect of Dezocine Versus Nalbuphine Combined With Sufentanil on Postoperative Analgesia, Complications, and Free Flap Survival in Patients Undergoing Oral Cancer Radical Surgery: A Randomized Controlled Clinical Trial.